Anders Bylock
Nessuna posizione attualmente
Profilo
Anders Bylock is former Chief Medical Officer of Alzinova AB, former Chief Medical Officer of Aptahem AB, former Senior Director-Global at Boehringer Ingelheim GmbH, former Director-Clinical Research at Merck Sharp & Dohme (Sweden) AB, former Director-Clinical Pharmacology & Drug at AstraZeneca AB and former Associate Professor at the University of Uppsala.
Precedenti posizioni note di Anders Bylock
Società | Posizione | Fine |
---|---|---|
ALZINOVA AB | Chief Tech/Sci/R&D Officer | 28/05/2023 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | Chief Tech/Sci/R&D Officer | 01/06/2022 |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Chief Tech/Sci/R&D Officer | - |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
University of Uppsala | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
Health Technology | |
ALZINOVA AB | Health Technology |
Aziende private | 3 |
---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Merck Sharp & Dohme (Sweden) AB
Merck Sharp & Dohme (Sweden) AB Medical DistributorsDistribution Services Part of Merck & Co., Inc., Merck Sharp & Dohme (Sweden) AB is a biopharmaceutical company based in Stockholm, Sweden. MSD Sweden is focused on inventing medicines and vaccines to save and improve lives, sharing a vision and mission to achieve this goal. The Swedish company was founded in 1974. The CEO is Björn Fredrik Niklas Andreasson. | Distribution Services |